The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; Merrimack
Consulting or Advisory Role - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; Ignyta; Janssen; Loxo; Merrimack; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - AbbVie; Adaptimmune; Bayer; Epizyme; Ignyta; Janssen; Loxo; Novartis; Pfizer
Patents, Royalties, Other Intellectual Property - Novartis
 
Consulting or Advisory Role - Epizyme (Inst)
 
Consulting or Advisory Role - Eisai; Janssen; Lilly; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Eisai
Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bayer; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Patrick Schoffski
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Robin Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Immune Design; Lilly; Merck
Research Funding - MSD
 
Mark Agulnik
No Relationships to Disclose
 
Victor Manuel Villalobos
Consulting or Advisory Role - Abbvie; Agios; Epizyme; Ignyta; Janssen; Lilly; Novartis
Travel, Accommodations, Expenses - Epizyme; GenMab; Janssen; Lilly; Xencor
 
Thierry Marie Jahan
Research Funding - Acerta Pharma (Inst); Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Lilly (Inst); Polaris (Inst); Trizell (Inst)
 
Tom Wei-Wu Chen
Honoraria - Eisai; Lilly; Novartis
Consulting or Advisory Role - Eisai
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
 
George D. Demetri
No Relationships to Disclose
 
Gregory Michael Cote
Consulting or Advisory Role - 2nd.MD; Advance Medical; Agios; Grand Rounds Health; InfiniteMD
Research Funding - Agios (Inst); Bavarian Nordic; Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Rashmi Chugh
Stock and Other Ownership Interests - Portola Pharmaceuticals
Consulting or Advisory Role - EMD Serono; Epizyme; Janssen
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Epizyme (Inst); Lilly (Inst); MabVax (Inst); Medivation/Pfizer (Inst); Morphotek (Inst); Novartis (Inst)
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); Genmab (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Abha A. Gupta
No Relationships to Disclose
 
Elizabeth T. Loggers
No Relationships to Disclose
 
Brian Van Tine
No Relationships to Disclose
 
Laura Sierra
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Jay Yang
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Anand Rajarethinam
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Mrinal M. Gounder
Honoraria - Amgen; Bayer; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TRACON Pharma
Consulting or Advisory Role - Amgen; Bayer; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Other Relationship - Desmoid Tumor Research Foundation